All In Biotech

Drug Trial Radar · NCT06350279

A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects

A Single and Multiple Ascending Dose Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jan 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Actual

Start

Dec 25, 2023

Primary completion

Aug 2, 2024

Study completion Sep 29, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, randomized, subject-blinded, placebo controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD),and food effect (FE) of HSK39297 following (1) a single ascending dose (part 1), (2) 10 days of multiple ascending dose (part 2), and (3) a single dose two-period crossover FE cohort.

Conditions

  • Healthy

Interventions

  • HSK39297Drug

    50-600mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number and severity of treatment emergent adverse events (TEAEs) .Time frame: 9 days after single dose and 16 days after the first dose of multiple doses

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.